CAPTRUST FINANCIAL ADVISORS
Position in SUPN — Supernus Pharmaceuticals, Inc.
CIK 1512024
RALEIGH, NC
Position in SUPN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$2,080,625
+$1,156,056 QoQ
Shares Held
40,252
+116.4% QoQ
Ownership
0.069%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2020
23 quarters on record
Voting authority
Sole 55.81337573288284.ToString("F0")%
Shared 0.ToString("F0")%
None 44.18662426711716.ToString("F0")%
Common Shares in SUPN Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026CAPTRUST FINANCIAL ADVISORS holds $56,556,259 across 24 Drug Manufacturers - Specialty & Generic names. SUPN ranks #7 (3.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
216,286 | $25,567,168 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
11,253 | $6,672,803 | |
| 3 | NBIX |
Neurocrine Biosciences Inc
|
37,584 | $4,951,316 | |
| 4 | HLN |
Haleon plc
|
371,702 | $3,720,737 | |
| 5 | TAK |
Takeda Pharmaceutical Co Ltd
|
158,629 | $2,937,809 | |
| 6 | VTRS |
Viatris Inc
|
199,616 | $2,696,812 | |
| 7 | SUPN |
Supernus Pharmaceuticals, Inc.
This page
|
40,252 | $2,080,625 | |
| 8 | HROW |
Harrow, Inc.
|
56,788 | $2,002,344 |
All Filings in SUPN
Export CSV
23 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,080,625 | 40,252 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $924,569 | 18,603 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $880,052 | 18,415 | Shares | Sole | 2025-11-19 | |
| 2025-06-30 | $643,386 | 20,412 | Shares | Sole | 2025-08-15 | |
| 2025-03-31 | $580,690 | 17,731 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $628,967 | 17,394 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $293,871 | 9,425 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $274,027 | 10,244 | Shares | Sole | 2024-08-15 | |
| 2024-03-31 | $352,390 | 10,331 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $256,321 | 8,857 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 | $285,597 | 10,359 | Shares | Sole | 2023-11-15 | |
| 2023-03-31 | $226,437 | 6,250 | Shares | Sole | 2023-05-15 | |
| 2022-12-31 | $215,482 | 6,041 | Shares | Sole | 2023-02-15 | |
| 2022-09-30 | $200,188 | 5,914 | Shares | Sole | 2022-11-16 | |
| 2022-06-30 | $92,659 | 3,204 | Shares | Sole | 2022-08-23 | |
| 2022-03-31 | $96,410 | 2,983 | Shares | Sole | 2022-05-16 | |
| 2021-12-31 | $33,038 | 1,133 | Shares | Sole | 2022-02-14 | |
| 2021-09-30 | $27,790 | 1,042 | Shares | Sole | 2021-11-16 | |
| 2021-06-30 | $27,587 | 896 | Shares | Sole | 2021-08-16 | |
| 2021-03-31 | $23,980 | 916 | Shares | Sole | 2021-05-17 | |
| 2020-12-31 | $6,919 | 275 | Shares | Sole | 2021-02-16 | |
| 2020-09-30 | $4,689 | 225 | Shares | Sole | 2020-11-17 | |
| 2020-06-30 | $4,156 | 175 | Shares | Sole | 2020-08-14 | |
| No filing history on record for this holder in this stock. | ||||||